Clinical Trial Update: Cevostamab Following CAR T Cell Therapy for RRMM [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 clinical trial evaluating Cevostamab after CAR T cell therapy in relapsed or refractory multiple myeloma, currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Cevostamab (cevostamab)

Snippet

Sponsor: University of Pennsylvania | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING